Common stock
- Symbol
- DARE
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Dare Bioscience, Inc.
DARENASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item Submission 5.07 of Matters to a Vote of Security Holders. A special meeting of stockholders (the “Meeting”) of Daré Bioscience, Inc. (“Daré,” “we,” “us,” or “our”) was held on November 10, 2026 and the following proposals were voted upon by our stockholders. The proposals are described in detail in our definitive proxy statement for the Meeting filed with the U.S.…
Company context
We are a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs. In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via Section 503B compounding. We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation. In addition to prescription-based offerings — both FDA-approved products and compounded drugs — we intend to bring to market select consumer health products that do not require a physician’s prescription, where appropriate based on product profile and market opportunity.
Current securities
Registered securities in this filing
DARE BIOSCIENCE, INC · 8-K · Filed 2026-11-12
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item Submission
5.07 of Matters to a Vote of Security Holders.
A
special meeting of stockholders (the “Meeting”) of Daré Bioscience, Inc. (“Daré,” “we,”
“us,” or “our”) was held on November 10, 2026 and the following proposals were voted upon by our stockholders.
The proposals are described in detail in our definitive proxy statement for the Meeting filed with the U.S. Securities and Exchange Commission
on October 6, 2026. Below is a brief description of, and the final results of the votes for, each proposal.
Proposal
1 : Our stockholders approved, in accordance with Nasdaq listing rules, the potential future issuance of shares of our common stock
upon the exercise of outstanding warrants by the votes set forth below.
Votes Votes Abstentions Broker
For Against Non-Votes
────────────────────────────────────────────────────────────────────────
5,320,515 2,369,554 38,382 —
Proposal
2 : Our stockholders approved an adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of
Proposal 1 if there were not sufficient votes at the time of the Meeting to approve Proposal 1 by the votes set forth below. The adjournment
authorized by Proposal 2 was not necessary because there were sufficient votes to approve Proposal 1.
Votes Votes Abstentions Broker
For Against Non-Votes
────────────────────────────────────────────────────────────────────────
5,364,004 2,311,408 53,039 —
-2-